Arundic acid has been experimented in vitro and in vivo as a potential neuroprotective agent. It modulates astrocyte activation by inhibiting the enhanced astrocytic synthesis of S-100β protein, responsible for inducing neuronal death. The phase II clinical trials for the treatment of acute ischemic stroke, as well as clinical development in other neurodegenerative diseases including amytrophic lateral sclerosis, Alzheimer's disease and Parkinson's disease are recently completed. There is no review published in this area since its discovery as potential neuroprotective agent and the various syntheses reported for this important non-natural compound. This review summarizes the studies towards the development of arundic acid as a neuroprotective agent, the biological studies in vitro and in vivo, the phase II trials and the various efforts made for its synthesis in the last two decades.
Keywords: Alzheimer‘s disease, astrocyte modulation, ischemic stroke, neuroprotection, Parkinson‘s disease, synthesis.
Selective Androgen Receptor Modulators Antagonize Apolipoprotein E4-Induced Cognitive Impairments
Letters in Drug Design & Discovery Consequences of Cannabinoid and Monoaminergic System Disruption in a Mouse Model of Autism Spectrum Disorders
Current Neuropharmacology State of the Art: Psychotherapeutic Interventions Targeting the Psychological Factors Involved in IBD
Current Drug Targets Semantic Memory Disorders in Alzheimers Disease: Clues from Semantic Priming Effects
Current Alzheimer Research Causes and Diagnosis of Alzheimers Disease: A Proteomics Approach
Current Proteomics On Some Physiological Aspects of Ethanol Repercussion on Neural and Cardiorenal Functions
Central Nervous System Agents in Medicinal Chemistry Harnessing the Power of SIRT1 and Non-coding RNAs in Vascular Disease
Current Neurovascular Research Involvement of the Serotonergic System in Cognitive and Behavioral Symptoms of Alzheimers Disease
Current Psychiatry Reviews A Case of Topiramate-Induced Epistaxis
Current Drug Safety Targeting Signal Transduction Pathways in the Treatment of Mood Disorders: Recent Insights into the Relevance of the Wnt Pathway
CNS & Neurological Disorders - Drug Targets Established and Emerging Therapies for Huntingtons Disease
Current Molecular Medicine Editorial (Thematic Issue: Towards New Approaches in Alzheimer’s Research and Alzheimer’s Disease)
Current Alzheimer Research Calcium-Sensing Receptors of Human Astrocyte-Neuron Teams: Amyloid-β-Driven Mediators and Therapeutic Targets of Alzheimer's Disease
Current Neuropharmacology Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium
Current Alzheimer Research Tau Oligomers as Potential Targets for Immunotherapy for Alzheimers Disease and Tauopathies
Current Alzheimer Research Commentary (Brilliant Blue G: What a Little More Colour Can Be)
CNS & Neurological Disorders - Drug Targets Neurologic and Cardiovascular Complications in Pediatric Life Threatening Imipramine Poisoning
Current Drug Safety PPARs as Drug Targets to Modulate Inflammatory Responses?
Current Drug Targets - Inflammation & Allergy Understanding the Complexities of Functional Ability in Alzheimer’s Disease: More Than Just Basic and Instrumental Factors
Current Alzheimer Research Matrix Metalloproteinase-9/Gelatinase B is a Putative Therapeutic Target of Chronic Obstructive Pulmonary Disease and Multiple Sclerosis
Current Pharmaceutical Biotechnology